Oncternal Therapeutics Volcan Bond
ONCTDelisted Stock | USD 0.53 0.00 0.00% |
Oncternal Therapeutics holds a debt-to-equity ratio of 0.002. . Oncternal Therapeutics' financial risk is the risk to Oncternal Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Oncternal Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Oncternal Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Oncternal Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Oncternal Therapeutics' stakeholders.
For most companies, including Oncternal Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Oncternal Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Oncternal Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Oncternal |
Given the importance of Oncternal Therapeutics' capital structure, the first step in the capital decision process is for the management of Oncternal Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Oncternal Therapeutics to issue bonds at a reasonable cost.
Popular Name | Oncternal Therapeutics Volcan Compania Minera |
Specialization | Biotechnology |
Equity ISIN Code | US68236P1075 |
Bond Issue ISIN Code | USP98047AC08 |
S&P Rating | Others |
Maturity Date | 11th of February 2026 |
Issuance Date | 11th of February 2021 |
Coupon | 4.375 % |
Oncternal Therapeutics Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
US68233JBV52 | US68233JBV52 | Details | |
US68233JBU79 | US68233JBU79 | Details | |
US68233JBR41 | US68233JBR41 | Details | |
US68233JBP84 | US68233JBP84 | Details | |
ONCOR ELEC DELIVERY | US68233JBG85 | Details | |
ONCOR ELEC DELIVERY | US68233JBH68 | Details | |
US68233JBD54 | US68233JBD54 | Details | |
ONCOR ELEC DELIVERY | US68233JBB98 | Details | |
ONCOR ELEC DELIVERY | US68233JAZ75 | Details | |
ONCOR ELEC DELIVERY | US68233JAS33 | Details | |
ONCOR ELEC DELIVERY | US68233JAT16 | Details | |
ONCOR ELEC DELIVERY | US68233JAH77 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
ONCOR ELEC DELIVERY | US68233DAT46 | Details | |
US682357AA69 | US682357AA69 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details | |
Valero Energy Partners | US91914JAA07 | Details | |
US68235PAH10 | US68235PAH10 | Details | |
ONE GAS INC | US68235PAG37 | Details | |
ONE GAS INC | US68235PAF53 | Details |
Understaning Oncternal Therapeutics Use of Financial Leverage
Oncternal Therapeutics' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Oncternal Therapeutics' current equity. If creditors own a majority of Oncternal Therapeutics' assets, the company is considered highly leveraged. Understanding the composition and structure of Oncternal Therapeutics' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. Oncternal Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. Please read more on our technical analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.